Why the study?
Reoperation on the tricuspid valve carries increased operative risk, making transcatheter valve-in-valve implantation an attractive alternative to high-risk redo surgery.
Is transcatheter tricuspid valve-in-valve implantation via a transatrial approach feasible and safe for treating a failed bioprosthetic tricuspid valve in a high-risk patient?
Is transcatheter tricuspid valve-in-valve implantation via a transatrial approach feasible and safe for treating a failed bioprosthetic tricuspid valve in a high-risk patient?
Transcatheter tricuspid valve-in-valve implantation via a transatrial approach is a technically feasible and safe alternative to high-risk redo surgery for dysfunctional surgical tricuspid bioprostheses.
Supports feasibility of transcatheter tricuspid valve-in-valve in high-risk redo cases; leaves open need for prospective outcome data.
Reoperation on the tricuspid valve after prior heart valve surgery is associated with an increased operative risk due to a poor clinical status with severe heart failure and late presentation. Transcatheter tricuspid valve-in-valve implantation emerged as an attractive alternative to a high-risk redo surgery. The authors report a case of successful treatment of a failed bioprosthetic tricuspid valve in a 58-year-old woman with severe heart failure, decompensated cardiac cirrhosis and atrial fibrillation using transcatheter tricuspid valve-in-valve implantation of a Sapien 3 valve (Edwards Lifesciences, Irvine, California) via a transatrial approach. This case demonstrates the efficiency of this novel approach for the treatment of dysfunctional surgical tricuspid bioprosthetic valves and the technical feasibility and safety of a rarely used route.
No takes yet. Share an insight, caveat, or question.
Tinică et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: